Feedback / Questions
Kisqali (ribociclib) - Novartis
Kisqali: Regulatory submission for HR+, HER2(-) breast cancer (adjuvant) in 2022
(Novartis)
-
Dec 6, 2019 -
R&D Day
Regulatory
https://www.novartis.com/sites/www.novartis.com/files/2019-12-05-novartis-r-d-day-investor-presentation.pdf
Dec 6, 2019
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious